Anti-PDGF/bFGF sheep monoclonal antibody

Drug Profile

Anti-PDGF/bFGF sheep monoclonal antibody

Latest Information Update: 14 May 2001

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator KS Biomedix Holdings; St. Bartholomews Hospital
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Fibroblast growth factor inhibitors; Platelet-derived growth factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Coronary artery restenosis; Solid tumours; Vascular restenosis

Most Recent Events

  • 14 May 2001 Discontinued-Preclinical for Coronary artery restenosis in United Kingdom (Unknown route)
  • 14 May 2001 Discontinued-Preclinical for Solid tumours in United Kingdom (Unknown route)
  • 14 May 2001 Discontinued-Preclinical for Vascular restenosis in United Kingdom (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top